cardiometabolic disease

CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...

CARLSBAD, Calif., June 24, 2026 Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA®...

NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...

INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...

COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...

COPENHAGEN, Denmark, June 5, 2026 Zealand Pharma announced new results from its Phase 2 ZUPREME-1 clinical trial evaluating petrelintide,...

Basel, Switzerland, June 1, 2026 Roche announced that new clinical data from its obesity portfolio will be presented at...

CAMBRIDGE, Mass., May 20, 2026 MetaVia Inc. has announced the publication of new peer-reviewed preclinical research supporting the anti-fibrotic...

CAMBRIDGE, Mass., May 12, 2026 AIRNA announced new preclinical findings at the 2026 American Society of Gene and Cell...

SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...